News & Events
Welcome to our new Master students!
On 14 September, we welcomed 83 new Master students - 45 new students enrolled in our Biotechnology programme and 38 new students enrolled in our Computational Biology & Bioinformatics programme. Have a great start and enjoy your time at D-BSSE!
We wish all students a good start into the semester.
From ETH research to laboratories worldwide: MaxWell Biosystems turns 10
Founded as an ETH Zurich spin-off in 2016, MaxWell Biosystems has grown into a global company bringing advanced electrophysiology technology from academic research into laboratories worldwide, helping scientists study how neurons and other electrically active cells function, communicate, and respond to disease and treatment.
Advancing drug discovery: AI-guided workflow boosts chemical reaction prediction with minimal data
Modern drug discovery relies heavily on modifying existing chemical structures to quickly create new potential medicines, a process that usually requires time-consuming and expensive laboratory testing. To overcome this bottleneck, scientists at D-BSSE and Roche jointly developed a smart, automated approach that combines artificial intelligence (AI) with laboratory experiments to reliably predict chemical reactions much faster and with fewer trial-and-error tests.
Congratulations on your promotion to Full Professor!
On 23 and 24 September, upon application of Joël Mesot, President of ETH Zurich, the ETH Board appointed five new professors and promoted three, amongst them: Konrad Tiefenbacher, D-BSSE faculty member and associated professor at both ETH Zurich and University of Basel. Congratulations on your promotion to Full Professor!
Clean sweep for cutting-edge research
From biotech and engineering to the latest work in physics – many scientific breakthroughs start life in the clean room. ETH researchers enjoy access to top-notch facilities in Basel and Zurich.
Well-BSSE-ing: A year dedicated to wellbeing at D-BSSE
On 17 September, D-BSSE launches Well-BSSE-ing, a year-long programme promoting physical and mental wellbeing. D-BSSE members can explore a year of talks, workshops, activities and shared experiences that support wellbeing, strengthen connections and foster a culture where everyone can thrive, both professionally and personally.
Meet Ariel Tennenhouse deciphering how immune repertoires evolve
Fascinated by the evolution of immune repertoires, the chemical biologist from the San Francisco Bay Area, USA, joined D-BSSE for its world-class research environment and thriving biotech ecosystem. So far, the science has impressed him – and so has summer in Basel.
A warm welcome to our new Master students!
On 14 September, we were delighted to welcome 83 new Master students to D-BSSE: 45 joining our Biotechnology programme and 38 starting Computational Biology & Bioinformatics. We wish you a fantastic start and a rewarding time at D-BSSE!
ETH Public Tour: Cleanroom - Microtechnology for Biomedicine
On 24 November, 6:15 pm, the Bio Engineering Lab led by Andreas Hierlemann and the Cleanroom Facility Basel are inviting the public to a 1-hour guided tour to gain an insight into the fascinating world of micro- and nanotechnology manufacturing and applications in biomedical research (tour in German; please register).
“There are things about drug discovery that you simply cannot learn from a textbook”
For the past two years, Sylke Poehling has been enrolled at the department as our first Professor of Practice. Sylke is an experienced leader in the pharmaceutical and biotech industry, with over 25 years of experience. She currently serves in senior leadership roles at Roche, including heading therapeutic modalities and gene therapy. In this interview, she talks about her role as a bridge builder between academia and industry.
Spin-off InSphero enters a new chapter in human-relevant drug development
Since its beginnings as an ETH Zurich spin-off, InSphero has worked to bring human-relevant 3D in vitro biology into pharmaceutical research. Recent developments mark a new chapter in that journey, expanding the company’s capabilities across spheroids, organoids, imaging, and phenotypic analysis at a time when New Approach Methodologies (NAMs) are gaining momentum across drug development.